Although some encouraging results have been achieved in targeting CCL2 or its receptors as an antitumoral strategy, three clinical trials targeting the CCL2-CCR2 axis with the humanized neutralizing anti-CCR2 mAb (MLN1202) and a humanized monoclonal CCL2 neutralizing antibody (CNTO 888) were unsuccessful in suppressing tumor growth and metastasis in solid tumors [12–14]. This evidence concerns the gene CCL2 and neoplasm.